As of 2024-12-12, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -4.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 154.79 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -33.92 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.3x - 7.1x | 7.1x |
| Forward P/E multiples | 7.1x - 7.8x | 7.2x |
| Fair Price | (2.87) - (0.09) | (1.65) |
| Upside | -269.7% - -105.4% | -197.2% |
| Date | EV/EBITDA |
| 2024-12-06 | -4.06 |
| 2024-12-05 | -3.77 |
| 2024-12-04 | -3.92 |
| 2024-12-03 | -3.80 |
| 2024-12-02 | -3.78 |
| 2024-11-29 | -3.92 |
| 2024-11-28 | -3.96 |
| 2024-11-27 | -3.90 |
| 2024-11-26 | -3.94 |
| 2024-11-25 | -3.93 |
| 2024-11-22 | -4.18 |
| 2024-11-21 | -4.17 |
| 2024-11-20 | -4.30 |
| 2024-11-19 | -4.03 |
| 2024-11-18 | -4.11 |
| 2024-11-15 | -3.96 |
| 2024-11-14 | -4.16 |
| 2024-11-13 | -4.38 |
| 2024-11-12 | -4.54 |
| 2024-11-11 | -4.48 |
| 2024-11-08 | -4.36 |
| 2024-11-07 | -4.39 |
| 2024-11-06 | -4.41 |
| 2024-11-05 | -4.42 |
| 2024-11-04 | -4.51 |
| 2024-11-01 | -4.58 |
| 2024-10-31 | -4.65 |
| 2024-10-30 | -4.63 |
| 2024-10-29 | -4.55 |
| 2024-10-28 | -4.52 |
| 2024-10-25 | -4.58 |
| 2024-10-24 | -4.41 |
| 2024-10-23 | -4.59 |
| 2024-10-22 | -4.67 |
| 2024-10-21 | -4.82 |
| 2024-10-18 | -4.98 |
| 2024-10-17 | -5.04 |
| 2024-10-16 | -5.10 |
| 2024-10-15 | -5.06 |
| 2024-10-14 | -5.07 |
| 2024-10-11 | -5.10 |
| 2024-10-10 | -5.11 |
| 2024-10-09 | -5.13 |
| 2024-10-08 | -5.18 |
| 2024-10-07 | -5.18 |
| 2024-10-04 | -5.19 |
| 2024-10-03 | -5.22 |
| 2024-10-02 | -5.29 |
| 2024-10-01 | -5.29 |
| 2024-09-30 | -5.34 |